Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
SEC filings, financial facts, source resources, and Goglides workspace context for D.R. Horton, Inc..
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
A CRISPR Therapeutics five-year double thesis focused on CASGEVY commercialization, cash runway, in-vivo pipeline proof, clinical risk, and dilution discipline.
OpenA Coverage Bootstrap CRISPR Therapeutics company evaluation covering CASGEVY, in-vivo editing, pipeline optionality, cash runway, commercialization, clinical risk, dilution, and valuation framework.
OpenD.R. Horton reported fiscal first-half 2026 revenue of $14.45 billion, net income of $1.24 billion, cash of $1.92 billion and operating cash flow of $441.5 million. The thesis turns on orders, incentives, gross margin, land inventory and balance-sheet discipli
OpenTag facets appear after tag usage counts are rebuilt.